Diabetic kidney disease (DKD) is the most common cause of end-stage kidney disease. Blood pressure (BP) control can reduce the risks of cardiovascular (CV) morbidity, mortality, and kidney disease progression. Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines have suggested the implementation of a more intensive BP control with a target systolic BP (SBP) of <120 mmHg based on the evidence that the CV benefits obtained is outweighed by the kidney injury risk associated with a lower BP target. However, an extremely low BP level may paradoxically aggravate renal function and CV outcomes. Herein, we aimed to review the existing literature regarding optimal BP control using medications for DKD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827046PMC
http://dx.doi.org/10.5049/EBP.2022.20.2.39DOI Listing

Publication Analysis

Top Keywords

kidney disease
20
blood pressure
8
pressure control
8
diabetic kidney
8
kidney
5
disease
5
control patients
4
patients diabetic
4
disease diabetic
4
disease dkd
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!